<DOC>
	<DOCNO>NCT00440167</DOCNO>
	<brief_summary>This crossover trial perform advanced metastatic pancreatic cancer previously expose chemotherapy . The study compare standard arm gemcitabine plus erlotinib experimental arm capecitabine plus erlotinib . It first trial kind incorporate second-line treatment study design . Patient fail first-line therapy switch comparator chemotherapy without erlotinib . The trial therefore compare two different regimen first-line treatment , also compare two sequential treatment strategy .</brief_summary>
	<brief_title>Capecitabine/Erlotinib Followed Gemcitabine Versus Gemcitabine/Erlotinib Followed Capecitabine</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Age 18 75 year Histologically proven pancreatic cancer stage III IV ( T13 N1M0 T1 3N0 1M1 ) No option resection curative intent At least one measurable measurable lesion ( accord RECIST ) No previous chemotherapy systemic tumor therapy No previous radiation PerformanceStatus 02 accord WHO/ECOG Life expectancy least 3 month Adequate kidney , liver bone marrow function , define Absolute neutrophil count * 1,5 x 109/l Hemoglobin * 8 g/dl Thrombocytes * 100 x 109/l Bilirubin * 2 x upper norm ( liver mets &lt; 5fold ) Serum Creatinine * 1,25 x upper norm Creatinine clearance &gt; 30 ml/min ( Cockroft/Gault ) Transaminases * 2,5 x upper norm ( liver mets &lt; 5fold ) Possibility regular longterm followup Negative pregnancy test woman childbearing age All patient must sign inform consent study entry . Known secondary cancer curatively treat basalioma carcinoma situ cervix uteri Clinically unstable CNSmetastases Known hypersensitivity study medication Severe impairment renal function ( creatinine clearance &lt; 30 ml/min ) Severe impairment liver function ( bilirubin &gt; 2,0 x upper norm , transaminases &gt; 2,5 x upper norm , know liver metastasis &gt; 5 x upper norm ) Clinically relevant disease cardiovascular system vital organ Known polyneuropathy Known DPDdeficiency ( screen require ) Simultaneous treatment antiviral agent sorivudin chemically related agent brivudin Pregnancy , lactation lack reliable contraception woman childbearing age Mental disease , drug alcohol abuse Participation another clinical trial within last 4 week All disease may prevent adequate participation trial Indication lack compliance study regulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>capecitabine</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>advanced</keyword>
</DOC>